DN001 botulinum toxin type A for moderate to severe glabellar lines

Phase 2, randomised, double-blind trial of DN001 in glabellar furrowing (8 arms), sponsored by Peking University First Hospital. Primary endpoints: Incidence of adverse events, serious adverse events, and injection site reactions within 28 days, Incidence of clinically significant abnormal changes in laboratory tests, ECG, vital signs, and physical examination within 28 days and 2 more. Planned start Aug 2024; status: not yet recruiting.